WO2009048633A3 - Chimeric chikungunya virus and uses thereof - Google Patents

Chimeric chikungunya virus and uses thereof Download PDF

Info

Publication number
WO2009048633A3
WO2009048633A3 PCT/US2008/011716 US2008011716W WO2009048633A3 WO 2009048633 A3 WO2009048633 A3 WO 2009048633A3 US 2008011716 W US2008011716 W US 2008011716W WO 2009048633 A3 WO2009048633 A3 WO 2009048633A3
Authority
WO
WIPO (PCT)
Prior art keywords
virus
chikungunya virus
chimeric
chimeric chikungunya
discloses
Prior art date
Application number
PCT/US2008/011716
Other languages
French (fr)
Other versions
WO2009048633A2 (en
Inventor
Llya V. Frolov
Scott C. Weaver
Eryu Wang
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of WO2009048633A2 publication Critical patent/WO2009048633A2/en
Priority to US12/798,796 priority Critical patent/US8343506B2/en
Publication of WO2009048633A3 publication Critical patent/WO2009048633A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention discloses a chimeric Chikungunya virus comprising a heterologous alphavirus cDNA fragment and a Chikungunya virus cDNA fragment. The heterologous alphavirus may include but is not limited to Sindbis virus, Eastern equine encephalitis virus or Venezuelan equine encephalitis virus. The present invention also discloses the use of this chimeric Chikungunya virus as vaccines and in serological and diagnostic assays.
PCT/US2008/011716 2007-10-11 2008-10-14 Chimeric chikungunya virus and uses thereof WO2009048633A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/798,796 US8343506B2 (en) 2007-10-11 2010-04-12 Chimeric chikungunya virus and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99854807P 2007-10-11 2007-10-11
US60/998,548 2007-10-11

Publications (2)

Publication Number Publication Date
WO2009048633A2 WO2009048633A2 (en) 2009-04-16
WO2009048633A3 true WO2009048633A3 (en) 2010-07-22

Family

ID=40083868

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/011716 WO2009048633A2 (en) 2007-10-11 2008-10-14 Chimeric chikungunya virus and uses thereof

Country Status (2)

Country Link
US (1) US8343506B2 (en)
WO (1) WO2009048633A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2519266T3 (en) * 2009-12-31 2017-11-06 Medigen Inc Infectious DNA vaccines against Chikungunya virus
US9441032B2 (en) 2010-04-07 2016-09-13 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
EP2374816B1 (en) * 2010-04-07 2016-09-28 Agency For Science, Technology And Research Binding molecules against Chikungunya virus and uses thereof
US9422529B2 (en) * 2010-12-22 2016-08-23 The Board Of Regents Of The University Of Texas System Alphavirus compositions and methods of use
CN105483139B (en) * 2014-09-16 2019-08-02 中国人民解放军军事医学科学院微生物流行病研究所 A kind of DNA molecular and application thereof comprising chikungunya virus full-length genome cDNA
FI3393510T3 (en) 2015-12-23 2023-03-22 Valneva Austria Gmbh Zika virus vaccine
EP3684404A1 (en) * 2017-09-21 2020-07-29 Valneva SE Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CN111742053A (en) 2017-12-20 2020-10-02 Vlp 治疗有限责任公司 Alphavirus replicon particles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505719A (en) * 1995-05-23 1999-05-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Alphavirus RNA replicon system
US6168923B1 (en) * 1994-04-18 2001-01-02 The Wistar Institute Of Anatomy And Biology Compositions and methods for use of IL-12 as an adjuvant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AU771774B2 (en) * 1998-12-07 2004-04-01 U.S. Medical Research Institute Of Infectious Diseases Live attenuated Venezuelan equine encephalitis vaccine
EP1399183B1 (en) * 2001-05-31 2010-06-30 Novartis Vaccines and Diagnostics, Inc. Chimeric alphavirus replicon particles
MXPA05012754A (en) * 2003-05-29 2006-05-17 Army Medical Res Inst For I Live attenuated viral vaccines for eastern equine encephalitis virus.
NZ550818A (en) * 2004-05-18 2009-09-25 Alphavax Inc TC-83-derived alphavirus vectors, particles and methods
WO2008030220A2 (en) * 2005-08-11 2008-03-13 The Board Of Regents Of The University Of Texas System Chikungunya virus infectious clones and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168923B1 (en) * 1994-04-18 2001-01-02 The Wistar Institute Of Anatomy And Biology Compositions and methods for use of IL-12 as an adjuvant
JPH11505719A (en) * 1995-05-23 1999-05-25 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Alphavirus RNA replicon system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VANLANDINGHAM, D.L. ET AL.: "'Determinants of Vector Specificity ofO'NYONG NYONG and Chikungunya Viruses in ANOPHELES and AEDES mosquitoes'", AM. J. TROP. MED. HYG., vol. 74, no. 4, 2006, pages 663 - 669 *
WANG, E. ET AL.: "Chimeric Alphavirus Vaccine Candidates for Chikungunya", VACCINE, vol. 26, 8 August 2008 (2008-08-08), pages 5030 - 5039 *

Also Published As

Publication number Publication date
WO2009048633A2 (en) 2009-04-16
US8343506B2 (en) 2013-01-01
US20110171249A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2009048633A3 (en) Chimeric chikungunya virus and uses thereof
WO2012040037A8 (en) Soy adhesives and composites made from the adhesives
EP1863941A4 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2009016639A3 (en) Multimeric multiepitope influenza vaccines
TW201614067A (en) Virus like particle comprising modified envelope protein E3
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2013023732A8 (en) Ternesite used as an activator for latent-hydraulic and pozzolanic materials
WO2009131604A3 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2007134876A8 (en) HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
IL190775A (en) Influenza virus-like particles, vaccines containing the same and uses thereof
WO2007014930A3 (en) Polyammonium/polysiloxane copolymers
WO2007098267A3 (en) Pseudoinfectious flavivirus and uses thereof
WO2011056899A3 (en) Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
WO2007141593A3 (en) Process for the preparation of metoprolol and its salts
WO2006131936A3 (en) Hepatitis c virus vaccine
WO2012076566A3 (en) Aqueous adhesive composition comprising a synthetic polymer and lupin protein
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
IL219801A0 (en) ANTI-C4.4a ANTIBODIES AND USES THEREOF
WO2010120874A3 (en) Chimeric therapeutics, compositions, and methods for using same
GB2467491A8 (en) Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies.
WO2009120380A3 (en) Recombinant rhinovirus vectors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08837255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08837255

Country of ref document: EP

Kind code of ref document: A2